Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 828 participants.
Also called NCT05650411
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 828 participants
- Sponsor
- Registry
-
NCT05650411
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Switzerland
- Registry status
- Recruiting
Technical summary
Registry record NCT05650411. Randomized; single masking; primary purpose treatment. Start 2026-04-26 (actual); primary completion 2028-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)
- Acronym
- ULTIMATE-LM
- Condition
- Left Main Coronary Artery Stenosis
- Intervention (Device)
- LMCA PCI (percutaneous coronary intervention) with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).
- Intervention (Drug)
- P2Y12 inhibitor-based SAPT after short DAPT
- Intervention (Drug)
- Conventional DAPT
- Lead sponsor
- IGLESIAS Juan Fernando
- Collaborator
- University of Bern
Record details
- Record id
cardio:ct-nct05650411- Content hash
9b59d563def3daf44bcb8e56fb75e4f9123c1b20cce911a0783245f88be9690a